Provectus BIOPHARMACEUTICALS, Inc. (PVCT) intrinsic value & 10-year financials
Provectus BIOPHARMACEUTICALS, Inc. (PVCT) has a Graham intrinsic value of $0.45 per share. At $0.05 on Oct 17, 2026, the stock trades 89% below that value. Over the last 10 fiscal years revenue shrank 30.2% a year to $336.1K, with an average return on invested capital of 52.0%.
- Graham intrinsic value
- $0.45
- Share price (Oct 17, 2026)
- $0.05
- Price vs Graham value
- 89% below
- Market cap
- $21.0M
- Revenue (FY2025)
- $336.1K
- Revenue growth (10-yr CAGR)
- -30.2%
- ROIC (10-yr avg)
- 52.0%
- Free cash flow (FY2025)
- —
PVCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $336.1K | -$5.4M | -$0.01 | — | -1575.3% | 88.2% |
| FY2024 | $617.1K | -$4.7M | -$0.01 | — | -734.4% | 69.0% |
| FY2023 | $557.7K | -$3.1M | -$0.01 | — | -520.2% | 44.9% |
| FY2022 | $989.0K | -$3.6M | -$0.01 | — | -346.6% | 57.5% |
| FY2021 | — | -$5.5M | — | — | — | — |
| FY2020 | — | -$6.7M | — | — | — | 24.4% |
| FY2019 | — | -$6.9M | — | — | — | 28.2% |
| FY2018 | — | -$8.2M | — | — | — | — |
| FY2017 | — | -$13.5M | — | -$10.4M | — | — |
| FY2016 | — | -$24.4M | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PROVECTUS BIOPHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PROVECTUS BIOPHARMACEUTICALS, INC. has earned high returns on invested capital, averaging 52.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
PROVECTUS BIOPHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PROVECTUS BIOPHARMACEUTICALS, INC. is modeled at -30.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.45 per share.